Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ziv Aflibercept in Myopic CNV, CRVO and Resistant DME
NCT04290195Phase 2Completed
- Start
- Jun 2019
- Primary completion
- Dec 2019
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of aflibercept in myopic choroidal neovascularization (mCNV), diabetic macular edema (DME), central retinal vein occlusion (CRVO). Started Jun 2019; status: completed.
02
Drugs
aflibercept
03
Conditions
myopic choroidal neovascularization (mCNV)diabetic macular edema (DME)central retinal vein occlusion (CRVO)
Beyond the preview
Go deeper on NCT04290195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04290195.